wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5
Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
P2860
Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26766368-9824AB36-AFBA-49E5-BCF3-63A5CADECDC5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0be6ca4736245b55d5f91721cff71805c4bcd468
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.